2-[methyl-11C]Methoxyestradiol: synthesis, evaluation and pharmacokinetics for in vivo studies on angiogenesis

Nuclear Medicine and Biology

Volumn 34, Issue 6, 2007, Pages 625-631

  Lee, Iljung ^a   Seong Choe, Yearn ^a   Jung, Kyung Ho ^a   Lee, Kyung Han ^a   Young Choi, Joon ^a   Choi, Yong ^a   Kim, Byung Tae ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

2 methyl 11C Methoxyestradiol; Angiogenesis; HUVECs; Pharmacokinetics

Indexed keywords

2 METHYLMETHOXYESTRADIOL C 11; ESTRADIOL DERIVATIVE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DETERMINATION; DRUG HALF LIFE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; RADIATION DETECTION; RADIOCHEMISTRY; TISSUE DISTRIBUTION; UMBILICAL VEIN;

ANIMALS; AREA UNDER CURVE; BIOTRANSFORMATION; CARBON RADIOISOTOPES; CARCINOMA, LEWIS LUNG; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ESTRADIOL; HALF-LIFE; HUMANS; INDICATORS AND REAGENTS; MICE; MUSCLE, SMOOTH, VASCULAR; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 34547830386     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2007.06.004     Document Type: Article

References (20)

1. Folkman J. Tumor angiogenesis: a possible control point in tumor growth. Ann Intern Med 82 (1975) 96-100
2. Battegay E.J. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 73 (1995) 333-346
3. Fotsis T., Zhang Y., Pepper M.S., Adlercreutz H., Montesano R., Nawroth P.P., et al. The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth. Nature 368 (1994) 237-239
4. Klauber N., Parangi S., Flynn E., Hamel E., and D'Amato R.J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol. Cancer Res 57 (1997) 81-86
5. Mukhopadhyay T., and Roth J.A. Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene 14 (1997) 379-384
6. Newman S.P., Leese M.P., Purohit A., James D.R.C., Rennie C.E., Potter B.V.L., et al. Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates. Int J Cancer 109 (2004) 533-540
7. D'Amato R.J., Lin C.M., Flynn E., Folkman J., and Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicines site. Proc Natl Acad Sci U S A 91 (1994) 3964-3968
8. Cushman M., He H.-M., Katzenellenbogen J.A., Lin C.M., and Hamel E. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem 38 (1995) 2041-2049
9. Huang P., Feng L., Oldham E.A., Keating M.J., and Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407 (2000) 390-395
10. Mooberry S.L. New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr Opin Oncol 15 (2003) 425-430
11. Dahut W.L., Lakhani N.J., Gulley J.L., Arlen P.M., Kohn E.C., Kotz H., et al. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 5 (2006) 22-27
12. Ireson C.R., Chander S.K., Purohit A., Perera S., Newman S.P., Parish D., et al. Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. Br J Cancer 90 (2004) 932-937
13. Sweeney C., Liu G., Yiannoutsos C., Kolesar J., Horvath D., Staab M.J., et al. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res 11 (2005) 6625-6633
14. Kiuru P.S., and Wähälä K. Short synthesis of 2-methoxyestradiol and 2-hydroxyestradiol. Steroids 68 (2003) 373-375
15. Song S.H., Jung K.H., Paik J.Y., Koh B.H., Bae J.S., Choe Y.S., et al. Distribution and pharmacokinetic analysis of angiostatin radioiodine labeled with high stability. Nucl Med Biol 32 (2005) 845-850
16. Jung K.H., Kim D.H., Paik J.Y., Ko B.H., Bae J.S., Choe Y.S., et al. Pharmacokinetics and biodistribution of a small radioiodine labeled nerve growth factor fragment. Ann Nucl Med 20 (2006) 535-540
17. Paaren HE, Duff SR. Synthesis of 2-hydroxyestradiol derivatives. US Patent 6448419, September 10, 2002.
18. 11C]methoxyestradiol for in vivo studies of tumor angiogenesis. J Labelled Compd Radiopharm 42 (1999) S432-S433
19. Takaku T., Kimura Y., and Okuda H. Isolation of an antitumor compound from Agaricus blazei Murill and its mechanism of action. J Nutr 131 (2001) 1409-1413
20. Longcope C., Flood C., Femino A., and Williams K.I.H. Metabolism of 2-methoxyestrone in normal men. J Clin Endocrinol Metab 57 (1980) 277-282